Open an account

Soligenix

SNGX · NASDAQ

$0.3546+$0.0109 (+3.17%)TodayMarket closed ·
Prev close $0.3437

About SNGX

Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. The company is headquartered in Princeton, New Jersey and currently employs 13 full-time employees. The Company’s segments include Specialized Biotherapeutics, and Public Health Solutions. Its Specialized BioTherapeutics business segment is engaged in developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious diseases and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2).

Employees
13
Headquarters
Princeton, New Jersey
Listed
Apr 4, 1994
Sector
Health Care
Industry
Biotechnology
Website
soligenix.com

SNGX key statistics

Market cap
7.72M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
188.71K
Volume
81.15K
Open price
$0.344
High today
$0.3639
Low today
$0.3384
52 Week high
$1.76
52 Week low
$0.28

Soligenix (SNGX) at a glance

As of Oct 20, 2026, Soligenix (SNGX) shares are priced at $0.3546, giving the company a market cap of 7.72M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.3384 and $0.3639. The current price is 4.8% above the day's low and 2.6% below its high.

Volume so far is 81.15K shares, below the average of 188.71K shares a day.

Over the past year Soligenix has ranged from $0.28 to $1.76, and now sits 5% of the way up that range.

Soligenix met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.12 per share against an estimate of -$0.1581.

SNGX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 23.9% on average.

  1. Q3 FY24: reported -$0.78 per share against an estimate of -$1.11
  2. Q4 FY24: reported -$1.14 per share against an estimate of -$0.969
  3. Q1 FY25: reported -$1.06 per share against an estimate of -$0.6834
  4. Q2 FY25: reported -$0.82 per share against an estimate of -$0.9384
  5. Q3 FY25: reported -$0.58 per share against an estimate of -$0.5661
  6. Q4 FY25: reported -$0.28 per share against an estimate of -$0.5712
  7. Q1 FY26: reported -$0.28 per share against an estimate of -$0.2856
  8. Q2 FY26: reported -$0.12 per share against an estimate of -$0.1581

SNGX news

  • Press releasePRNewswire

    Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results

  • Press releasePRNewswire

    Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine

  • Avi Kapoor

    Crude Oil Falls Over 5%; Dycom Industries Shares Surge Following Q1 Results

  • Avi Kapoor

    Dow Jumps Over 300 Points; Dick's Sporting Shares Fall After Q1 Results

  • Mohd Haider

    Soligenix (SNGX) Stock Soars 72% On ThermoVax Platform Promise Amid Ebola Outbreak Caused By Bundibugyo Virus

  • Press releasePRNewswire

    Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo

  • Press releasePRNewswire

    Soligenix Announces Recent Updates and First Quarter 2026 Financial Results

  • Avi Kapoor

    Crude Oil Gains Over 3%; General Motors Earnings Top Views

Similar companies

Companies in the same industry as Soligenix

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.